Revenio Group Oyj (HEL:REG1V), a health technology company focussing on ophthalmic products, announced on Monday that it has appointed Mikko Moilanen as the CEO of the company, effective on 5 August 2019.
Timo Hildén, the previous CEO, will continue to lead the integration work of CenterVue acquisition.
Previously, Moilanen was the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, He also held the position of CEO of Suunto Oy and he has held several international management positions in Nokia Plc.
Revenio Group consists of Icare Finland Oy, Icare USA Inc, Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
Arch Oncology Names Dennison to Board of Directors
Palladio Biosciences Names Martin Chief Executive Officer
Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D.
Vor Biopharma Names Ang as President and Chief Executive Officer
Catabasis Pharmaceuticals Names Cole to its Board of Directors
Altasciences Names Setnik as Chief Scientific Officer
Exicure Names Muralidhar, Hau to its Board of Directors
Seres Therapeutics Names Berenson to its Board of Directors
Ribon Therapeutics Names Parasuraman as Chief Medical Officer, Stewart as Chief Business Officer
Pilatus Comparator Solutions names new Vice President North America